切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2022, Vol. 11 ›› Issue (06) : 441 -451. doi: 10.3877/cma.j.issn.2095-3224.2022.06.001

所属专题: 指南共识

指南与共识

超全直肠系膜切除层面的原发性直肠癌和局部复发直肠癌盆腔脏器联合切除中国专家共识(2023版)
中国盆腔脏器联合切除协作组, 中国医师协会结直肠肿瘤专业委员会, 中国医疗保健国际交流促进会胃肠外科学分会   
  • 收稿日期:2022-11-14 出版日期:2022-12-25
  • 基金资助:
    国家自然科学基金(81903023,82072732); 吴阶平医学基金会临床科研专项资助基金课题(320.6750.2021-04-2); 中国医学科学院肿瘤医院“希望之星”人才项目

Chinese expert consensus on the pelvic exenteration for primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 edition)

China PelvEx Collaborative, Colorectal Cancer Committee of the Chinese Medical Doctor Association, Gastrointestinal Surgery Committee of China International Exchange and Promotive Association for Medical and Health Care   

  • Received:2022-11-14 Published:2022-12-25
引用本文:

中国盆腔脏器联合切除协作组, 中国医师协会结直肠肿瘤专业委员会, 中国医疗保健国际交流促进会胃肠外科学分会. 超全直肠系膜切除层面的原发性直肠癌和局部复发直肠癌盆腔脏器联合切除中国专家共识(2023版)[J]. 中华结直肠疾病电子杂志, 2022, 11(06): 441-451.

China PelvEx Collaborative, Colorectal Cancer Committee of the Chinese Medical Doctor Association, Gastrointestinal Surgery Committee of China International Exchange and Promotive Association for Medical and Health Care. Chinese expert consensus on the pelvic exenteration for primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 edition)[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(06): 441-451.

超全直肠系膜切除层面的原发性直肠癌(PRC-bTME)和局部复发直肠癌(LRRC)患者经盆腔脏器联合切除手术(PE)治疗后,部分患者可获得长期生存,但需要面临巨大手术创伤、围手术期严重并发症、器官功能永久性丧失及生活质量下降等风险。因此,术前评估应强调多学科协作,制定个体化诊疗措施。应遵循肿瘤功能外科原则和手术损伤效益比原则,强调R0根治切除,降低围手术期并发症发生率,减少外科手术创伤及器官功能丧失,以寻找到最佳的质量控制和平衡点。本共识由中国医师协会结直肠肿瘤专业委员会和中国医疗保健国际交流促进会胃肠外科学分会牵头组织,在总结国内外研究进展及专家经验的基础上形成初稿;经专家组成员讨论、审阅与修改,经过对各项主要观点进行无记名投票,并按照循证医学的原则进行深入论证,最终形成《超全直肠系膜切除层面的原发性直肠癌和局部复发直肠癌盆腔脏器联合切除中国专家共识(2023版)》。本共识主要针对PRC-bTME和LRRC施行PE的适应证、禁忌证、术前诊断评估、围手术期治疗以及PE 的切除范围、手术方式、相关器官的重建、PE的安全性及其并发症、术后随访等问题进行归纳整理,旨在为PRC-bTME和LRRC规范实施PE手术提供指导意见。

Pelvic exenteration is often required for primary rectal cancer beyond totalmesorectal excision (PRC-bTME) and locally recurrent rectal cancer (LRRC). Some patients with radical resection can achieve long-term survival, but they need to face risks, such as huge surgical trauma, serious perioperative complications, permanent loss of organ function and decline in quality of life. The preoperative evaluation of PRC-bTME and LRRC should emphasize multidisciplinary collaboration, and develop individualized diagnosis and treatment strategies. The principles of function preservation in oncology surgery and risk-benefit balance should be followed, and R0 resection should be emphasized. Perioperative complications, surgical trauma and organ function loss should be minimized to achieve the best quality control and balance point. This consensus was formulated by the Colorectal Cancer Committee of the Chinese Medical Doctor Association and the Gastrointestinal Surgery Committee of China International Exchange and Promotive Association for Medical and Health Care. The draft was formed based on the summary of domestic and foreign research progress and expert experience. After discussion, review and modification by experts, a secret ballot was conducted for each major opinion, and in-depth demonstration was carried out according to the principles of evidence-based medicine. Finally, the Chinese expert consensus on the pelvic exenteration with primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 edition) was formed. This consensus mainly summarizes the indications and contraindications of PE for PRC-bTME and LRRC, preoperative diagnosis and evaluation, perioperative treatment, as well as the resection scope, surgical methods, reconstruction of related organs, safety and complications of PE, postoperative follow-up and other issues, in order to provide guidance for PRC-bTME and LRRC to perform PE.

表1 推荐分级的评估、制定与评价(GRADE)证据质量描述2
图1 盆腔解剖分区(唐彬绘制)
图2 局部复发直肠癌(LRRC)中国分型示意图(唐彬绘制)。 2A: 轴向型;2B: 前向型;2C: 侧向型;2D: 后向型(骶骨型);2E: 侧盆壁型;2F: 混合型
表2 局部复发直肠癌(LRRC)中国分型及其定义、R0切除率和相对预后16, 17, 18
图3 超TME层面的原发性直肠癌(PRC-bTME)和局部复发直肠癌(LRRC)患者术前评估流程
图4 不同盆腔脏器切除术的切除范围示意图(唐彬绘制)。4A:全盆腔脏器切除术(TPE);4B:前盆腔脏器切除术(APE);4C:后盆腔脏器切除术(PPE);4D:后盆腔脏器联合骶骨切除术
图5 常见泌尿系统重建示意图(唐彬绘制)。5A:输尿管对端吻合;5B:输尿管膀胱再植;5C:输尿管膀胱瓣吻合;5D:膀胱部分切除修补术;5E:回肠膀胱(Bricker)术;5F:输尿管皮肤造口
《超全直肠系膜切除层面的原发性直肠癌和局部复发直肠癌盆腔脏器联合切除中国专家共识(2023版)》编审委员会专家组成员名单(按姓氏笔画排序)
主任委员
王锡山 中国医学科学院肿瘤医院
汪 欣 北京大学第一医院
委员会成员
于向阳 天津市南开医院
马腾辉 中山大学附属第六医院
王 权 吉林大学第一医院
王刚成 河南省肿瘤医院
王自强 四川大学华西医院
王志刚 上海市第六人民医院
王贵玉 哈尔滨医科大学附属第二医院
王贵英 河北医科大学附属第二医院
王晰程 北京大学肿瘤医院
邓海军 南方医科大学南方医院
白文佩 首都医科大学世纪坛医院
冯 波 上海交通大学医学院附属瑞金医院
毕小刚 山西省人民医院
朱玉萍 浙江省肿瘤医院
刘 正 中国医学科学院肿瘤医院
刘海义 中国医学科学院肿瘤医院山西医院
刘 超 四川省肿瘤医院
刘 骞 中国医学科学院肿瘤医院
汤坚强 中国医学科学院肿瘤医院
许剑民 复旦大学附属中山医院
孙 轶 天津人民医院
孙跃明 南京医科大学附属第一医院
杜斌斌 甘肃省人民医院
李心翔 复旦大学附属肿瘤医院
李正荣 南昌大学附属第一医院
李 军 浙江大学医学院附属第二医院
李学松 北京大学第一医院
李 波 云南大学附属医院
杨春康 福建省肿瘤医院
吴小剑 中山大学附属第六医院
吴 斌 北京协和医院
邱剑光 中山大学附属第六医院
佟伟华 吉林大学第一医院
张 卫 海军军医大学附属长海医院
张 剑 海军军医大学附属长征医院
陈瑛罡 中国医学科学院肿瘤医院深圳医院
武爱文 北京大学肿瘤医院
武颖超 北京大学第一医院
林建江 浙江大学医学院附属第一医院
季 刚 空军军医大学西京医院
项建斌 复旦大学附属华山医院
胡 刚 中国医学科学院肿瘤医院河北医院
姚宏伟 首都医科大学北京友谊医院
袁维堂 郑州大学第一附属医院
郭 鹏 北京大学人民医院
唐 源 中国医学科学院肿瘤医院
黄 平 南京医科大学附属逸夫医院
黄 颖 福建医科大学附属协和医院
温 冰 北京大学第一医院
谢忠士 吉林大学中日联谊医院
撰稿组成员:汤坚强、武颖超、庄孟、唐彬、张剑、马腾辉、王晰程、唐源
执笔统筹:汤坚强
绘图
唐 彬 湘潭市中心医院
[1]
Consensus statement on the multidisciplinary manage-ment of patients with recurrent and primary rectal can-cer beyond total mesorectal excision planes[J]. Br J Surg, 2013, 100(8): 1009-1014.
[2]
Harbour R, Miller J. A new system for grading recom-mendations in evidence based guidelines[J]. BMJ, 2001, 323(7308): 334-336.
[3]
Miner TJ, Jaques DP, Paty PB, et al. Symptom control in patients with locally recurrent rectal cancer[J]. Ann Surg Oncol, 2003, 10(1): 72-79.
[4]
Malcolm FL, Adiamah A, Banerjea A, et al. Long-term health-related quality of life following colorectal cancer surgery: patient-reported outcomes in a remote follow-up population[J]. Colorectal Dis, 2021, 23(1): 213-225.
[5]
Nolte S, Liegl G, Petersen MA, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15, 386 persons across 13 European countries, Canada and the Unites States[J]. Eur J Cancer, 2019, 107: 153-163.
[6]
Mizukami Y, Ueda S, Mizumoto A, et al. Diffusion-weighted magnetic resonance imaging for detecting lymph node metastasis of rectal cancer[J]. World J Surg, 2011, 35(4): 895-899.
[7]
中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会结直肠肿瘤专业委员会腹腔镜专业委员会, 中华医学会外科学分会结直肠外科学组. 中国直肠癌侧方淋巴结转移诊疗专家共识(2019版) [J]. 中华胃肠外科杂志, 2019, 22(10): 901-912.
[8]
Lu YY, Chen JH, Chien CR, et al. Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis[J]. Int J Colorectal Dis, 2013, 28(8): 1039-1047.
[9]
Kau T, Reinprecht P, Eicher W, et al. FDG PET/CT in the detection of recurrent rectal cancer[J]. Int Surg, 2009, 94(4): 315-324.
[10]
Watson AJ, Lolohea S, Robertson GM, et al. The role of pos-itron emission tomography in the management of recur-rent colorectal cancer: a review[J]. Dis Colon Rectum, 2007, 50(1): 102-114.
[11]
Plodeck V, Rahbari NN, Weitz J, et al. FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences[J]. Eur Radiol, 2019, 29(1): 422-428.
[12]
Matsuyama T, Yamauchi S, Masuda T, et al. Treatment and subsequent prognosis in locally recurrent rectal cancer: a multicenter retrospective study of 498 patients[J]. Int J Colorectal Dis, 2021, 36(6): 1243-1250.
[13]
裴炜, 熊斌, 崔书中, 等. 结直肠癌腹膜转移预防和治疗腹腔用药中国专家共识(V2019) [J/CD]. 中华结直肠疾病电子杂志, 2019, 8(4): 329-335.
[14]
Boyle KM, Sagar PM, Chalmers AG, et al. Surgery for locally recurrent rectal cancer[J]. Dis Colon Rectum, 2005, 48(5): 929-937.
[15]
Moore HG, Shoup M, Riedel E, et al. Colorectal cancer pelvic recurrences: determinants of resectability[J]. Dis Colon Rectum, 2004, 47(10): 1599-1606.
[16]
张峻岭, 吴涛, 陈国卫, 等. 局部复发直肠癌手术根治性和预后的影响 因素分析[J]. 中华胃肠外科杂志, 2020, 23(5): 472-479.
[17]
郭鹏, 王畅, 杨晓东, 等. 直肠癌骶前复发不同手术方式的临床疗效比较[J]. 中华胃肠外科杂志, 2020, 23(5): 466-471.
[18]
中国医师协会外科医师分会结直肠外科医师委员会, 中国医师协会结直肠肿瘤专业委员会器官功能保护专业委员会, 中国医师协会肛肠医师分会, 等. 直肠癌骶前复发诊疗专家共识[J]. 中华胃肠外科杂志, 2020, 23(5): 438-444.
[19]
Li Y, Wang J, Ma X, et al. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Int J Biol Sci, 2016, 12(8): 1022-1031.
[20]
Kong JC, Soucisse M, Michael M, et al. Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and meta-analysis of oncological and operative outcomes[J]. Ann Surg Oncol, 2021, 28(12): 7476-7486.
[21]
Denost Q, Frison E, Salut C, et al. A phase Ⅲ randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer-GRECCAR 15 trial protocol[J]. Colorectal Dis, 2021, 23(7): 1909-1918.
[22]
CollaborativePelvEx. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study(PelvEx II)[J]. BJS Open, 2021, 5(3): zrab029.
[23]
Fahy MR, Kelly ME, Power Foley M, et al. The role of intraoperative radiotherapy in advanced rectal cancer: a meta-analysis[J]. Colorectal Dis, 2021, 23(8): 1998-2006.
[24]
Cameron MG, Kersten C, Vistad I, et al. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer-a systematic review[J]. Acta Oncol, 2014, 53(2): 164-173.
[25]
Dijkstra EA, Mul V, Hemmer P, et al. Re-Irradiation in patients with recurrent rectal cancer is safe and feasible[J]. Ann Surg Oncol, 2021, 28(9): 5194-5204.
[26]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)结直肠癌诊疗指南2022[M]. 北京: 人民卫生出版社, 2022.
[27]
Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer [J]. N Engl J Med, 2022, 386(25): 2363-2376.
[28]
Yang TX, Morris DL, Chua TC. Pelvic exenteration for rectal cancer: a systematic review[J]. Dis Colon Rectum, 2013, 56(4): 519-531.
[29]
Lee DJ, Sagar PM, Sadadcharam G, et al. Advances in surgical management for locally recurrent rectal cancer: How far have we come? [J]. World J Gastroenterol, 2017, 23(23): 4170-4180.
[30]
Dozois EJ, Privitera A, Holubar SD, et al. High sacrectomy for locally recurrent rectal cancer: Can long-term survival be achieved?[J]. J Surg Oncol, 2011, 103(2): 105-109.
[31]
CollaborativePelvEx. Minimally invasive surgery tech-niques in pelvic exenteration: a systematic and meta-anal-ysis review[J]. Surg Endosc, 2018, 32(12): 4707-4715.
[32]
Sun Y, Yang H, Zhang Z, et al. Fascial space priority approach for laparoscopic total pelvic exenteration in patients with locally advanced rectal cancer[J]. Surg Endosc, 2022, 36(8): 6331-6335.
[33]
Kazi M, Kumar N, Rohila J, et al. Minimally invasive versus open pelvic exenterations for rectal cancer: a comparative analysis of perioperative and 3-year oncological outcomes [J]. BJS Open, 2021, 5(5): zrab074.
[34]
Tang J, Liu J, Du B, et al. Short- and long-term outcomes of laparoscopic versus open pelvic exenteration for locally advanced rectal cancer: a single-center propensity score matching analysis[J]. Tech Coloproctol, 2022.
[35]
左帅, 陈贺凯, 郑利军, 等. 腹腔镜后盆腔脏器切除术治疗局部进展期直肠癌临床效果分析[J]. 结直肠肛门外科, 2020, 26(2): 148-153.
[36]
Yang K, Cai L, Yao L, et al. Laparoscopic total pelvic exenteration for pelvic malignancies: the technique and short-time outcome of 11 cases[J]. World J Surg Oncol, 2015, 13: 301.
[37]
Nagasaki T, Akiyoshi T, Ueno M, et al. Laparoscopic salvage surgery for locally recurrent rectal cancer[J]. J Gastrointest Surg, 2014, 18(7): 1319-1326.
[38]
CollaborativePelvEx. Palliative pelvic exenteration: A systematic review of patient-centered outcomes[J]. Eur J Surg Oncol, 2019, 45(10): 1787-1795.
[39]
Chen YG, Liu YL, Jiang SX, et al. Adhesion pattern and prognosis studies of T4N0M0 colorectal cancer following en bloc multivisceral resection: evaluation of T4 subclassification[J]. Cell Biochem Biophys, 2011, 59(1): 1-6.
[40]
王锡山. 结直肠癌联合脏器切除得与失及临床病理分期的思考[J]. 中国实用外科杂志, 2010, 30(12): 1002-1004.
[41]
陈瑛罡, 刘彦龙, 刘正, 等. 原发ⅡC期结直肠癌患者炎性浸润与癌性浸润预后的比较研究[J]. 中华胃肠外科杂志, 2011, 14(4): 267-270.
[42]
Kazi M, Rohila J, Kumar NA, et al. Urinary reconstruction following total pelvic exenteration for locally advanced rectal cancer: complications and factors affecting outcomes[J]. Langenbecks Arch Surg, 2021, 406(2): 329- 337.
[43]
Johnson YL, West MA, Gould LE, et al. Empty pelvis syn-drome: asystematic review of reconstruction techniques and their associated complications[J]. Colorectal Dis, 2022, 24(1): 16-26.
[44]
程文悦, 杨旭霞, 陈思诗, 等. 不同组织来源生物补片降解性能的比较研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2021, 15(1): 97-101.
[45]
谢昆, 温冰, 翟伟, 等. 穿支皮瓣在修复会阴区肿瘤术后缺损中的应用[J]. 中华整形外科杂志, 2018, 34(9): 704-708.
[46]
Bogner A, Fritzmann J, Müssle B, et al. Pelvic exenteration for colorectal and non-colorectal cancer: a comparison of perioperative and oncological outcome[J]. Int J Colorectal Dis, 2021, 36(8): 1701-1710.
[47]
Rausa E, Kelly ME, Bonavina L, et al. A systematic review examining quality of life following pelvic exenteration for locally advanced and recurrent rectal cancer[J]. Colorectal Dis, 2017, 19(5): 430-436.
[48]
Konstantinidis IT, Lee B, Trisal V, et al. National postoperative and oncologic outcomes after pelvic exenteration for T4b rectal cancer[J]. J Surg Oncol, 2020, 122(4): 739-744.
[49]
CollaborativePelvEx. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration[J]. Ann Surg, 2019, 269(2): 315-321.
[50]
Moghadamyeghaneh Z, Hwang GS, Hanna MH, et al. Surgical site infection impact of pelvic exenteration procedure[J]. J Surg Oncol, 2015, 112(5): 533-537.
[51]
Rutledge FN, Smith JP, Wharton JT, et al. Pelvic exenteration: analysis of 296 patients[J]. Am J Obstet Gynecol, 1977, 129(8): 881-892.
[52]
Jimenez RE, Shoup M, Cohen AM, et al. Contemporary outcomes of total pelvic exenteration in the treatment of colorectal cancer[J]. Dis Colon Rectum, 2003, 46(12): 1619-1625.
[53]
Khan O, Patsouras D, Ravindraanandan M, et al. Total Pelvic Exenteration for Locally Advanced and Recurrent Rectal Cancer: Urological Outcomes and Adverse Events [J]. Eur Urol Focus, 2021, 7(3): 638-643.
[54]
Hagemans J, Voogt E, Rothbarth J, et al. Outcomes of urinary diversion after surgery for locally advanced or locally recurrent rectal cancer with complete cystectomy; ileal and colon conduit[J]. Eur J Surg Oncol, 2020, 46(6): 1160-1166.
[55]
Venchiarutti RL, Solomon MJ, Koh CE, et al. Pushing the boundaries of pelvic exenteration by maintaining survival at the cost of morbidity[J]. Br J Surg, 2019, 106(10): 1393-1403.
[56]
Radwan RW, Jones HG, Rawat N, et al. Determinants of survival following pelvic exenteration for primary rectal cancer[J]. Br J Surg, 2015, 102(10): 1278-1284.
[57]
Kaur M, Joniau S, D'hoore A, et al. Pelvic exenterations for gynecological malignancies: a study of 36 cases[J]. Int J Gynecol Cancer, 2012, 22(5): 889-896.
[58]
Sutton PA, Brown K, Ebrahimi N, et al. Long-term surgical complications following pelvic exenteration: operative management of the empty pelvis syndrome[J]. Colorectal Dis, 2022.
[59]
Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell free DNA by ultradeep sequencing in patients with stages I to Ⅲ colorectal cancer[J]. JAMA Oncol, 2019, 5(8): 1124-1131.
[60]
CollaborativePelvEx. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer[J]. Br J Surg, 2018, 105(6): 650-657.
[1] 中华医学会骨科分会关节外科学组, 中国医师协会运动医学医师分会, 海军军医大学附属长海医院. 中轴型脊柱关节炎诊断和治疗专家共识(2023年版)[J]. 中华关节外科杂志(电子版), 2023, 17(02): 151-160.
[2] 中华医学会烧伤外科学分会小儿烧伤学组. 儿童烧伤早期休克液体复苏专家共识(2023版)[J]. 中华损伤与修复杂志(电子版), 2023, 18(05): 371-376.
[3] 黄跃生. 努力建设高水平创面修复新学科[J]. 中华损伤与修复杂志(电子版), 2023, 18(03): 185-187.
[4] 中国老年医学学会烧创伤分会. 老年患者皮肤撕裂伤防护专家共识(2022版)[J]. 中华损伤与修复杂志(电子版), 2023, 18(02): 98-103.
[5] 倪鑫淼, 王磊, 王潇, 陈志远, 翁小东, 刘修恒. 前列腺癌患者骨保护现状及临床用药进展[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(02): 191-195.
[6] 李咏生, 孙建国, 李梦侠, 重庆肺癌精准治疗协作组(CPLOG). 第三代EGFR-TKI耐药后诊疗策略专家共识[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 145-155.
[7] 中国研究型医院学会微创外科学专业委员会. 日间腹腔镜胆囊切除术专家共识[J]. 中华腔镜外科杂志(电子版), 2023, 16(04): 193-199.
[8] 静脉淋巴功能不全临床专家共识编写组. 静脉淋巴功能不全临床专家共识[J]. 中华临床医师杂志(电子版), 2023, 17(06): 630-638.
[9] 杨旭希, 郑吉洋, 陈秀梅, 陈淑玲, 杨峻青, 苏芝琪, 左咏臻, 广东省医师协会心力衰竭专业医师分会, 广东省护士协会介入护士分会. 慢性心力衰竭患者容量管理护理专家共识[J]. 中华介入放射学电子杂志, 2023, 11(03): 201-207.
[10] 中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会. 普通心脏起搏器和植入型心律转复除颤器手术操作规范中国专家共识(2023)[J]. 中华心脏与心律电子杂志, 2023, 11(02): 65-102.
[11] 中华医学会消化内镜学分会. 中国经口胆胰管镜超级微创诊疗技术共识意见(2023年,北京)[J]. 中华胃肠内镜电子杂志, 2023, 10(04): 217-239.
[12] 中华医学会消化内镜学分会护理协作组. 消化内镜中心的环境与布局专家共识建议(2023年,北京)[J]. 中华胃肠内镜电子杂志, 2023, 10(04): 240-247.
[13] 中华医学会消化内镜学分会. 消化内镜超级微创手术创面预处理与抗生素应用专家共识(2023年,北京)[J]. 中华胃肠内镜电子杂志, 2023, 10(02): 83-91.
[14] 中华医学会消化内镜学分会. 中国结直肠息肉冷切专家共识(2023年,杭州)[J]. 中华胃肠内镜电子杂志, 2023, 10(02): 73-82.
[15] 中国医师协会外科医师分会肥胖和糖尿病外科医师委员会, 中国肥胖代谢外科研究协作组. 肥胖代谢外科个案管理术前临床路径中国专家共识(2023版)[J]. 中华肥胖与代谢病电子杂志, 2023, 09(02): 73-82.
阅读次数
全文


摘要